699374AB0
Paratek Pharmaceuticals Inc
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that develops and sells specialty medicines, including NUZYRA, a once-daily antibiotic for pneumonia and skin infections, and XHANCE, a prescription nasal spray. It was founded in 1996 by Nobel Prize-winning scientist Walter Gilbert and antibiotic-resistance expert Stuart Levy, and went public in 2014 through a reverse merger with Transcept Pharmaceuticals. NUZYRA is a next-generation tetracycline engineered to dodge the two main ways bacteria resist older antibiotics.
CONVERTIBLEUnderlying: PRTKCUSIP: 699374AB0HealthcareUS1 derivative reporter
4.75% Convertible Senior Subordinated Notes due 2024
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
